Shares of Express Scripts Holding Company (NASDAQ:ESRX) ended Monday session in red amid volatile trading. The shares closed down -0.57 points or -0.81% at $69.96 with 3.43 million shares getting traded. Post opening the session at $70.24, the shares hit an intraday low of $69.30 and an intraday high of $70.53 and the price vacillated in this range throughout the day. The company has a market cap of $44.45 billion and the numbers of outstanding shares have been calculated to be 630.22 million shares.
Express Scripts Holding Company (ESRX) launched its Inflammatory Conditions Care Value Program℠, a comprehensive approach to control costs and improve care for people with inflammatory conditions like rheumatoid arthritis, psoriasis and Crohn’s Disease.
Through the combination of indication-specific formulary management and refunds for early discontinuation of therapy, this new program is the nation’s most comprehensive approach to better align a drug’s price with the value that drug provides a patient.
“Painful inflammatory conditions like rheumatoid arthritis can cripple patients and obliterate payer budgets,” said Glen Stettin, MD, Senior Vice President and Chief Innovation Officer at Express Scripts. “By finding creative ways to take better care of patients and protect our clients’ budgets, Express Scripts is uniquely tackling one of the biggest health challenges facing our country.”
Approximately ten million Americans live with an inflammatory condition. The biologic medications used to treat these conditions became the country’s costliest therapy class in 2015, representing 9.8 percent of all U.S. pharmacy spending. Express Scripts forecasts that, left unchecked, total U.S. spending on these medications will nearly double from 2015 to 2018.
Shares of Exelixis, Inc. (NASDAQ:EXEL) ended Monday session in red amid volatile trading. The shares closed down -0.07 points or -0.55% at $12.72 with 5.56 million shares getting traded. Post opening the session at $12.99, the shares hit an intraday low of $12.43 and an intraday high of $12.99 and the price vacillated in this range throughout the day. The company has a market cap of $3.05 billion and the numbers of outstanding shares have been calculated to be 230.33 million shares.
Exelixis, Inc. (EXEL) announced that the company and its partner Ipsen will jointly host a live investor and media briefing at the European Society for Medical Oncology (ESMO) 2016 Congress. The event will be held on Monday, October 10, 2016, with the program beginning at 19:00 CEST (local Copenhagen time) / 1:00 p.m. EDT / 10:00 a.m. PDT following on-site registration starting at 18:30 CEST.
During the briefing, Exelixis and Ipsen management and invited guests will discuss and provide context for clinical data for cabozantinib presented at the ESMO 2016 Congress. Key topics will include CABOSUN, the randomized phase 2 trial of cabozantinib compared with sunitinib in patients with previously untreated advanced renal cell carcinoma, which will be the subject of a late-breaking oral presentation during ESMO’s Presidential Symposium 3 earlier in the day. Presenters will also review data from the ongoing phase 1b trial evaluating the combination of cabozantinib and nivolumab in patients with genitourinary tumors.
The briefing will also be webcast live and available via conference call starting at 19:00 CEST / 1:00 p.m. EDT / 10 a.m. PDT on Monday, October 10. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under Investors & Media. Please connect to the company’s website at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be required to listen to the event. To participate by phone, please dial 855-299-5224 (domestic) or 631-267-4890 (international/toll dial) and use passcode 234-026-024. Please see the Event Calendar page for details on replay options once available.